Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2025 11:30 ET | Source: Lycia Therapeutics, Inc.

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
May 13, 2024 07:00 ET | Source: Lycia Therapeutics, Inc.

Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic

Lycia Therapeutics has completed a $106.6 million Series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic.
June 05, 2023 07:00 ET | Source: Lycia Therapeutics, Inc.

Lycia Therapeutics to Present at Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced that Aetna Wun Trombley, Ph.D., President and...
October 05, 2022 12:52 ET | Source: Lycia Therapeutics, Inc.

Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced that founder Carolyn Bertozzi, Ph.D., has been...
February 28, 2022 07:00 ET | Source: Lycia Therapeutics, Inc.

Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D.,...
September 09, 2021 07:00 ET | Source: Lycia Therapeutics, Inc.

Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures

-- Advancing novel targeted therapeutics using its LYTAC protein degradation technology -- -- Plans to use $105 million in recent capital, including $35 million upfront payment from strategic...